You Position: Home > Paper
Effect of cyclosporine A on cisplatin-induced apoptosis of hepatocellular carcinoma cells
( views:273, downloads:20 )
- Author:
- No author available
- Journal Title:
- WORLD CHINESE JOURNAL OF DIGESTOLOGY
- Issue:
- 31
- DOI:
- 10.3969/j.issn.1009-3079.2007.31.004
- Key Word:
- 肝癌;环孢素;顺铂;凋亡;噻唑蓝比色法;流式细胞仪
Abstract： 目的:探讨免疫抑制剂环孢素A(cyclosporine A,CsA)对顺铂(cisplatin,CDDP)诱导的肝癌细胞(hepatocelluar carcinoma cells,HCC)凋亡的影响及可能机制.方法:采用SMMC7721肝癌细胞进行培养,3d传一代.分成A组(空白对照)、B组(加入10mg/L的CsA)、C组(加入40 mg/L的CsA)、D组(加入20 mg/L的CDDP)、E组(加入10 mg/L的CsA+20 mg/L的CDDP)、F组(加入40 mg/L的CsA+20 mg/L的CDDP),在荧光显微镜下观察各组细胞的形态学变化,采用噻唑蓝(methyl thiazolyl tetrazolium,MTT)比色法测定细胞24h及48 h存活率,并用流式细胞仪检测各组细胞在24 h的凋亡率.结果:E, F组在倒置光学显微镜下呈现多量细胞坏死,凋亡小体较D组明显减少.D组凋亡率最高,为32.7%±2.8%;而E,F组凋亡率分别为22.7%±2.4%及22.8%±2.8%;A,B,C组凋亡率最低且组间差异不明显.E,F组与D组相比差异显著(P=0.008).结论:CsA可以抑制CDDP诱导的肝癌细胞凋亡.
- [1]Kang-Beom Kwon,Eun-Kyung Kim,Jung-Gook Lim,etc.Molecular mechanisms of apoptosis induced by Scorpio water extract in human hepatoma HepG2 cells[J].2005,(7).
- [2]张俊峰,陈规划,陆敏强,等.环孢素A与他克莫司对阿霉素治疗肝癌影响的实验研究[J].2006,(6).
- [3]高金亭,郑树森,梁廷波,等.环孢素或他克莫司联合表阿霉素对肝癌细胞增殖、凋亡的影响[J].2006,(5).
- [4]Thompson CB.APOPTOSIS IN THE PATHOGENESIS AND TREATMENT OF DISEASE [Review][J].1995,267(5203).
- [5]Dwayne J, Sutton,Paul B, Tchounwou.Mercury-induced externalization of phosphatidylserine and caspase 3 activation in human liver carcinoma (HepG2) cells.[J].2006,3(1).
- [6]Rassekh C,van der Sloot P,Tiu J,etc.Molecular basis of posttransplant squamous cell carcinoma: the potential role of cyclosporine a in carcinogenesis.[J].2006,116(5).
- [7]Waniek K,Malecki A,Stolecka A,etc.Inhibition of arachidonic acid release by cytosolic phospholipase A2 is involved in the antiapoptotic effect of FK506 and cyclosporin a on astrocytes exposed to simulated ischemia in vitro.[J].2006,102(1).
- [8]C E, Freise,L, Ferrell,T, Liu,etc.Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma.[J].1999,67.
- [9]Vogel W,Sandmueller H,Nachbaur K,etc.Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome.[J].2003,9(6).
- [10]Qian Ting,Feldtrauer JeanJacques,Waldmeier PeterC,etc.Inhibition of the mitochondrial permeability transition by the nonimmunosuppressive cyclosporin derivative NIM811.[J].2002,62(1).
- [11]Okamura M,Hashimoto K,Sakagami H,etc.Apoptosis-inducing activity of cisplatin (CDDP) against human hepatoma and oral squamous cell carcinoma cell lines.[J].2004,24(2B).
- [12]Poma P,Sanguedolce R,Maurici A,etc.Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production.[J].2006,28(4).
- [13]Yang B,Furness PN,Ashra SY,etc.Apoptosis and caspase-3 in long-term renal ischemia/reperfusion injury in rats and divergent effects of immunosuppressants.[J].2006,81(10).
- [14]Graeb C,Geissler EK,Jauch KW,etc.Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation.[J].2004,77(12).
- [15]Buccione R,Luini A,Pompeo A,etc.Cyclosporin A, but not FK506, increases arachidonic acid release and inhibits proliferation of pituitary corticotrope tumor cells.[J].1999,64(10).
- [16]Kienle K,Rentsch M,Beham A,etc.Caspase 3 inhibition improves survival and reduces early graft injury after ischemia and reperfusion in rat liver transplantation.[J].2004,78(9).
- [17]Bradham CA,Hatano E,Lemasters JJ,etc.The mitochondrial permeability transition augments Fas-induced apoptosis in mouse hepatocytes.[J].2000,275(16).
- [18]Armbruster N,Leverkus M,Kerstan A,etc.Cyclosporin A abolishes CD28-mediated resistance to CD95-induced apoptosis via superinduction of caspase-3.[J].2006,177(11).
- [19]Schlenke P,Fricke L,Hartel C,etc.Individual variability in cyclosporin A sensitivity: the assessment of functional measures on CD28-mediated costimulation of human whole blood T lymphocytes.[J].2003,23(2).